drugset / Trial / NCT00002868
Interferon-alfa With or Without Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
Phase 3
Completed
744 enrolled
Eastern Cooperative Oncology Group
National Cancer Institute (NCI) · collab
RandomizedTreatment
Summary
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining interferon alfa with high-dose chemotherapy and peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of interferon alfa with or without peripheral stem cell transplantation in treating patients who have newly diagnosed chronic myelogenous leukemia in chronic phase.
Timeline
- Start
- 1997-11-20
- Primary completion
- 2004-03
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cytarabine | Small molecule | — | Intravenous |
| Subject | interferon alfa | Protein / enzyme biologic | — | Subcutaneous |
| Background | Busulfan | Small molecule | — | Oral |
| Background | Etoposide | Small molecule | — | Intravenous |
| Background | Hydroxyurea | Other / unclassified | — | Intravenous |
| Background | Idarubicin | Small molecule | — | Intravenous |
| Background | filgrastim | Protein / enzyme biologic | — | Subcutaneous |